Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
WGc-043 by Chengdu WestGene Biopharma for T-Cell Lymphomas: Likelihood of Approval
WGc-043 is under clinical development by Chengdu WestGene Biopharma and currently in Phase I for T-Cell Lymphomas. According to GlobalData,...
WGc-043 by Chengdu WestGene Biopharma for Nasopharyngeal Cancer: Likelihood of Approval
WGc-043 is under clinical development by Chengdu WestGene Biopharma and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData,...
WGc-043 by Chengdu WestGene Biopharma for Epstein–Barr Virus (HHV-4) Infections: Likelihood of Approval
WGc-043 is under clinical development by Chengdu WestGene Biopharma and currently in Phase I for Epstein–Barr Virus (HHV-4) Infections. According...